These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18833005)

  • 1. An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases.
    Elkord E; Dangoor A; Drury NL; Harrop R; Burt DJ; Drijfhout JW; Hamer C; Andrews D; Naylor S; Sherlock D; Hawkins RE; Stern PL
    J Immunother; 2008; 31(9):820-9. PubMed ID: 18833005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
    Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients.
    Harrop R; Shingler W; Kelleher M; de Belin J; Treasure P
    J Immunother; 2010; 33(9):999-1005. PubMed ID: 20948436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).
    Elkord E; Dangoor A; Burt DJ; Southgate TD; Daayana S; Harrop R; Drijfhout JW; Sherlock D; Hawkins RE; Stern PL
    Cancer Immunol Immunother; 2009 Oct; 58(10):1657-67. PubMed ID: 19221742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
    Posner MC; Niedzwiecki D; Venook AP; Hollis DR; Kindler HL; Martin EW; Schilsky RL; Goldberg RM; Mayer RJ
    Ann Surg Oncol; 2008 Jan; 15(1):158-64. PubMed ID: 18008108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
    Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Melcher A; Nicholls J; Wassan H; Habib N; Anthoney A
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4487-94. PubMed ID: 17671134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial.
    Amato RJ; Drury N; Naylor S; Jac J; Saxena S; Cao A; Hernandez-McClain J; Harrop R
    J Immunother; 2008; 31(6):577-85. PubMed ID: 18528296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study.
    Amato RJ; Hawkins RE; Kaufman HL; Thompson JA; Tomczak P; Szczylik C; McDonald M; Eastty S; Shingler WH; de Belin J; Goonewardena M; Naylor S; Harrop R
    Clin Cancer Res; 2010 Nov; 16(22):5539-47. PubMed ID: 20881001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors.
    De Jong KP; Stellema R; Karrenbeld A; Koudstaal J; Gouw AS; Sluiter WJ; Peeters PM; Slooff MJ; De Vries EG
    Hepatology; 1998 Oct; 28(4):971-9. PubMed ID: 9755233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.
    Mazzaferro V; Coppa J; Carrabba MG; Rivoltini L; Schiavo M; Regalia E; Mariani L; Camerini T; Marchianò A; Andreola S; Camerini R; Corsi M; Lewis JJ; Srivastava PK; Parmiani G
    Clin Cancer Res; 2003 Aug; 9(9):3235-45. PubMed ID: 12960108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
    Amato RJ
    Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases.
    Katz SC; Pillarisetty V; Bamboat ZM; Shia J; Hedvat C; Gonen M; Jarnagin W; Fong Y; Blumgart L; D'Angelica M; DeMatteo RP
    Ann Surg Oncol; 2009 Sep; 16(9):2524-30. PubMed ID: 19568816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgeon's awareness of the synchronous liver metastases during colorectal cancer resection may affect outcome.
    Hamady ZZ; Malik HZ; Alwan N; Wyatt JI; Prasad KR; Toogood GJ; Lodge JP
    Eur J Surg Oncol; 2008 Feb; 34(2):180-4. PubMed ID: 17983724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphocytic infiltration surrounding liver metastases from colorectal cancer.
    Okano K; Maeba T; Moroguchi A; Ishimura K; Karasawa Y; Izuishi K; Goda F; Usuki H; Wakabayashi H; Maeta H
    J Surg Oncol; 2003 Jan; 82(1):28-33. PubMed ID: 12501166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55.
    Durrant LG; Maxwell-Armstrong C; Buckley D; Amin S; Robins RA; Carmichael J; Scholefield JH
    Clin Cancer Res; 2000 Feb; 6(2):422-30. PubMed ID: 10690519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.
    Foon KA; John WJ; Chakraborty M; Sherratt A; Garrison J; Flett M; Bhattacharya-Chatterjee M
    Clin Cancer Res; 1997 Aug; 3(8):1267-76. PubMed ID: 9815809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis.
    Gardini A; Ercolani G; Riccobon A; Ravaioli M; Ridolfi L; Flamini E; Ridolfi R; Grazi GL; Cavallari A; Amadori D
    J Surg Oncol; 2004 Jul; 87(1):46-52. PubMed ID: 15221919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases.
    Schoppmeyer K; Frühauf N; Oldhafer K; Seeber S; Kasimir-Bauer S
    Oncol Rep; 2006 Feb; 15(2):449-54. PubMed ID: 16391868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results.
    Liersch T; Meller J; Kulle B; Behr TM; Markus P; Langer C; Ghadimi BM; Wegener WA; Kovacs J; Horak ID; Becker H; Goldenberg DM
    J Clin Oncol; 2005 Sep; 23(27):6763-70. PubMed ID: 16170184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
    Conry RM; Curiel DT; Strong TV; Moore SE; Allen KO; Barlow DL; Shaw DR; LoBuglio AF
    Clin Cancer Res; 2002 Sep; 8(9):2782-7. PubMed ID: 12231517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.